Sen Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sen Jiang has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Bing Jie
Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
11 shared publicationsDong Yu
Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
11 shared publications- Bing Jie
Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
9 shared publications - Dong Yu
Department of Radiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China
9 shared publications Xu Ma
Department of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
7 shared publicationsLing-Ling Li
Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Intervent Radiol, Shanghai, Peoples R China
6 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e46945
Navigating the challenge – endovascular embolization of a giant bronchial artery aneurysm with a short, irregular neck: A case report
Rationale: Bronchial artery aneurysm (BAA) is a rare condition, but it can be life-threatening if the aneurysm ruptures. While endovascular therapy is the primary treatment, the selection of embolic material is limited by the tortuous and short aneurysm neck. Patient concerns: We report a huge, suspected ruptured BAA was unexpectedly detected in a 69-year-old man during a routine medical examination. Diagnoses: Enhanced chest computed tomography angiography and selective bronchial arteriography both revealed that the BAA was located at the proximal portion of the left bronchial artery It was characterized by a large aneurysm sac and a short, irregularly dilated aneurysm neck. Interventions: We successfully occluded the huge BAA using a single amplatzer vascular plug. Outcomes: The 6-month computed tomography angiography follow-up scan showed no signs of aneurysm recurrence. Lessons: Transcatheter embolization utilizing a single amplatzer vascular plug has proven to be an effective and cost-efficient treatment for BAAs that are characterized by a large aneurysm sac and a short, tortuous, irregularly dilated aneurysm neck.
- 16 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (3) , e46945
Open AccessNavigating the challenge – endovascular embolization of a giant bronchial artery aneurysm with a short, irregular neck: A case report
Rationale: Bronchial artery aneurysm (BAA) is a rare condition, but it can be life-threatening if the aneurysm ruptures. While endovascular therapy is the primary treatment, the selection of embolic material is limited by the tortuous and short aneurysm neck. Patient concerns: We report a huge, suspected ruptured BAA was unexpectedly detected in a 69-year-old man during a routine medical examination. Diagnoses: Enhanced chest computed tomography angiography and selective bronchial arteriography both revealed that the BAA was located at the proximal portion of the left bronchial artery It was characterized by a large aneurysm sac and a short, irregularly dilated aneurysm neck. Interventions: We successfully occluded the huge BAA using a single amplatzer vascular plug. Outcomes: The 6-month computed tomography angiography follow-up scan showed no signs of aneurysm recurrence. Lessons: Transcatheter embolization utilizing a single amplatzer vascular plug has proven to be an effective and cost-efficient treatment for BAAs that are characterized by a large aneurysm sac and a short, tortuous, irregularly dilated aneurysm neck.
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46176
Endovascular embolization for primary racemose hemangioma of the bronchial artery supplied by multiple systemic arteries: A rare case report
Rationale: Primary racemose hemangioma of the bronchial artery (RHBA) is a rare congenital vascular malformation, typically confined to the bronchial artery. Concomitant vascular supply originating from multiple non-bronchial systemic arteries (NBSAs) is exceedingly rare and significantly complicates treatment procedures. Patient concerns: We report an asymptomatic 66-year-old woman in whom incidental imaging revealed RHBA sustained by a complicated network of multiple systemic feeding arteries. Diagnoses: Chest computed tomography angiography and confirmatory selective arteriography revealed 6 markedly dilated, tortuous mediastinal arteries extending from the right subclavian artery to the abdominal aorta, terminating in multiple aneurysms clustered at the right hilum. Interventions: Successful endovascular embolization was achieved via super-selective catheterization and microcoils deployment. Six-month follow-up confirmed durable occlusion without recurrence. Lessons: RHBA with multi-source NBSAs involvement is rare. During interventional procedure, it must carefully consider the influence of diverse arterial blood flow on distal ectopic embolization, and omission of any feeding NBSAs can precipitate RHBA recurrence. In this case, carefully super-selective catheterization combined with microcoils deployment offered a safe, effective therapeutic option.
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46176
Open AccessEndovascular embolization for primary racemose hemangioma of the bronchial artery supplied by multiple systemic arteries: A rare case report
Rationale: Primary racemose hemangioma of the bronchial artery (RHBA) is a rare congenital vascular malformation, typically confined to the bronchial artery. Concomitant vascular supply originating from multiple non-bronchial systemic arteries (NBSAs) is exceedingly rare and significantly complicates treatment procedures. Patient concerns: We report an asymptomatic 66-year-old woman in whom incidental imaging revealed RHBA sustained by a complicated network of multiple systemic feeding arteries. Diagnoses: Chest computed tomography angiography and confirmatory selective arteriography revealed 6 markedly dilated, tortuous mediastinal arteries extending from the right subclavian artery to the abdominal aorta, terminating in multiple aneurysms clustered at the right hilum. Interventions: Successful endovascular embolization was achieved via super-selective catheterization and microcoils deployment. Six-month follow-up confirmed durable occlusion without recurrence. Lessons: RHBA with multi-source NBSAs involvement is rare. During interventional procedure, it must carefully consider the influence of diverse arterial blood flow on distal ectopic embolization, and omission of any feeding NBSAs can precipitate RHBA recurrence. In this case, carefully super-selective catheterization combined with microcoils deployment offered a safe, effective therapeutic option.
- 30 August 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (3) , 2024-2036
Pulmonary arterial blowout syndrome as a serious adverse event in patients with advanced lung cancer: a 12-year retrospective study
Objective Massive haemoptysis due to central pulmonary artery (CPA) rupture in patients with advanced lung cancer is a fatal complication with limited early diagnostic tools. This study aimed to identify risk factors associated with pulmonary artery rupture and to propose a grading model to facilitate early diagnosis and timely endovascular intervention. Materials and methods This retrospective study included patients with advanced lung cancer who experienced in-hospital sudden haemoptysis-related death and received endovascular treatment for CPA abnormalities. Propensity score matching (PSM; 1:2) balanced covariates between haemoptysis-related and other in-hospital deaths. Following PSM, multivariable logistic regression was performed to identify independent risk factors. Patients were categorised into two cohorts: Group A (2012–2018) and Group B (2019–2024), the latter reflecting the implementation of early detection and endovascular management. Overall survival (OS) was compared using Kaplan–Meier analysis and log-rank testing. Results Among 886 in-hospital deaths, sudden haemoptysis accounted for 4.63% (41/886), with 90.24% (37/41) exhibiting CPA abnormalities. CPA abnormalities, tumour necrosis, cavitation, and progressive bloody or malodorous sputum were identified as significant risk factors (p < 0.05). The haemoptysis group had significantly shorter OS than controls (p < 0.001). A three-tier grading system for pulmonary arterial blowout syndrome (PABS) was developed, with acute PABS being the most prevalent (67.26%). Patients in Group B demonstrated significantly improved OS compared with Group A (p < 0.001). Conclusion The PABS grading model enables risk stratification of life-threatening haemoptysis secondary to CPA rupture. Early identification and endovascular intervention may significantly improve clinical outcomes in advanced lung cancer. Key Points Question What are the clinical characteristics and risk stratification criteria for life-threatening haemoptysis arising from CPA rupture in advanced lung cancer? Findings In-hospital sudden haemoptysis mortality was 4.63% and strongly associated with CPA abnormalities. A PABS grading model characterises this fatal condition. Clinical relevance The PABS grading system enables early recognition of high-risk CPA rupture in advanced lung cancer. Prompt identification and endovascular intervention may substantially improve patient outcomes. Graphical Abstract
- 30 August 2025
- Published by Springer Nature in European Radiology
- Vol. 36 (3) , 2024-2036
Pulmonary arterial blowout syndrome as a serious adverse event in patients with advanced lung cancer: a 12-year retrospective study
Objective Massive haemoptysis due to central pulmonary artery (CPA) rupture in patients with advanced lung cancer is a fatal complication with limited early diagnostic tools. This study aimed to identify risk factors associated with pulmonary artery rupture and to propose a grading model to facilitate early diagnosis and timely endovascular intervention. Materials and methods This retrospective study included patients with advanced lung cancer who experienced in-hospital sudden haemoptysis-related death and received endovascular treatment for CPA abnormalities. Propensity score matching (PSM; 1:2) balanced covariates between haemoptysis-related and other in-hospital deaths. Following PSM, multivariable logistic regression was performed to identify independent risk factors. Patients were categorised into two cohorts: Group A (2012–2018) and Group B (2019–2024), the latter reflecting the implementation of early detection and endovascular management. Overall survival (OS) was compared using Kaplan–Meier analysis and log-rank testing. Results Among 886 in-hospital deaths, sudden haemoptysis accounted for 4.63% (41/886), with 90.24% (37/41) exhibiting CPA abnormalities. CPA abnormalities, tumour necrosis, cavitation, and progressive bloody or malodorous sputum were identified as significant risk factors (p < 0.05). The haemoptysis group had significantly shorter OS than controls (p < 0.001). A three-tier grading system for pulmonary arterial blowout syndrome (PABS) was developed, with acute PABS being the most prevalent (67.26%). Patients in Group B demonstrated significantly improved OS compared with Group A (p < 0.001). Conclusion The PABS grading model enables risk stratification of life-threatening haemoptysis secondary to CPA rupture. Early identification and endovascular intervention may significantly improve clinical outcomes in advanced lung cancer. Key Points Question What are the clinical characteristics and risk stratification criteria for life-threatening haemoptysis arising from CPA rupture in advanced lung cancer? Findings In-hospital sudden haemoptysis mortality was 4.63% and strongly associated with CPA abnormalities. A PABS grading model characterises this fatal condition. Clinical relevance The PABS grading system enables early recognition of high-risk CPA rupture in advanced lung cancer. Prompt identification and endovascular intervention may substantially improve patient outcomes. Graphical Abstract
- 1 January 2025
- Published by World Journal of Emergency Medicine in World Journal of Emergency Medicine
- Vol. 16 (3) , 197
Bronchial artery embolization for hemoptysis: a consensus statement by the Chinese College of Interventionalists
- 1 January 2025
- Published by World Journal of Emergency Medicine in World Journal of Emergency Medicine
- Vol. 16 (3) , 197
Bronchial artery embolization for hemoptysis: a consensus statement by the Chinese College of Interventionalists
- Open Access
- 14 October 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-6
Endovascular embolization of a congenital inferior phrenic artery-to-pulmonary arteriovenous malformation: a rare case report
Pulmonary arteriovenous malformation (PAVM) is abnormal arteriovenous shunts between pulmonary artery (PA) and pulmonary vein, and rarely has congenital direct communications with systemic arteries. A 33-year-old male presented to our hospital with intermittent bloody sputum with no evidence of pulmonary infection, trauma or surgery. Chest computed tomography angiography (CTA) indicated the congenital inferior phrenic artery (IPA)-to-PAVM surrounded by diffuse alveolar hemorrhage located in the lower lobe of right lung. Both the afferent PA and IPA were successfully embolized with coils. Recurrent hemoptysis did not occur during one-year follow up. The congenital communication between IPA and PAVM is rare, and the abnormal direct shunt would induce hemodynamically unstable condition within PAVM. Endovascular embolization of the afferent PA and IPA is a safe and effective method for this abnormal congenital shunt in lung.
- 14 October 2024
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 24 (1) , 1-6
Open AccessEndovascular embolization of a congenital inferior phrenic artery-to-pulmonary arteriovenous malformation: a rare case report
Pulmonary arteriovenous malformation (PAVM) is abnormal arteriovenous shunts between pulmonary artery (PA) and pulmonary vein, and rarely has congenital direct communications with systemic arteries. A 33-year-old male presented to our hospital with intermittent bloody sputum with no evidence of pulmonary infection, trauma or surgery. Chest computed tomography angiography (CTA) indicated the congenital inferior phrenic artery (IPA)-to-PAVM surrounded by diffuse alveolar hemorrhage located in the lower lobe of right lung. Both the afferent PA and IPA were successfully embolized with coils. Recurrent hemoptysis did not occur during one-year follow up. The congenital communication between IPA and PAVM is rare, and the abnormal direct shunt would induce hemodynamically unstable condition within PAVM. Endovascular embolization of the afferent PA and IPA is a safe and effective method for this abnormal congenital shunt in lung.
- Open Access
- 9 May 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (7) , 102446
Destroyed lung contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with post-tuberculosis bronchiectasis
- 9 May 2024
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17 (7) , 102446
Open AccessDestroyed lung contributes to the recurrence of hemoptysis after bronchial artery embolization in patients with post-tuberculosis bronchiectasis
- Open Access
- 18 March 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-12
Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study
Background: Nearly half of bronchiectasis patients receiving bronchial artery embolization (BAE) still have recurrent hemoptysis, which may be life-threatening. Worse still, the underlying risk factors of recurrence remain unknown. Methods: A retrospective cohort was conducted of patients with idiopathic bronchiectasis who received BAE from 2015 to 2019 at eight centers. Patients were followed up for at least 24 months post BAE. Based on the outcomes of recurrent hemoptysis and recurrent severe hemoptysis, a Cox regression model was used to identify risk factors for recurrence. Results: A total of 588 individuals were included. The median follow-up period was 34.0 months (interquartile range: 24.3–53.3 months). The 1-month, 1-year, 2-year, and 5-year cumulative recurrent hemoptysis-free rates were 87.2%, 67.5%, 57.6%, and 49.4%, respectively. The following factors were relative to recurrent hemoptysis: 24-h sputum volume (hazard ratio [HR] = 1.99 [95% confidence interval [95% CI]: 1.25–3.15, p = 0.015]), isolation of Pseudomonas aeruginosa (HR = 1.50 [95% CI: 1.13–2.00, p = 0.003]), extensive bronchiectasis (HR = 2.00 [95% CI: 1.29–3.09, p = 0.002]), and aberrant bronchial arteries (AbBAs) (HR = 1.45 [95% CI: 1.09–1.93, p = 0.014]). The area under the receiver operating characteristic curve of the nomogram was 0.728 [95% CI: 0.688–0.769]. Conclusions: Isolation of Pseudomonas aeruginosa is an important independent predictor of recurrent hemoptysis. The clearance of Pseudomonas aeruginosa might effectively reduce the hemoptysis recurrence rate.
- 18 March 2023
- Published by Springer Nature in Respiratory Research
- Vol. 24 (1) , 1-12
Open AccessPseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study
Background: Nearly half of bronchiectasis patients receiving bronchial artery embolization (BAE) still have recurrent hemoptysis, which may be life-threatening. Worse still, the underlying risk factors of recurrence remain unknown. Methods: A retrospective cohort was conducted of patients with idiopathic bronchiectasis who received BAE from 2015 to 2019 at eight centers. Patients were followed up for at least 24 months post BAE. Based on the outcomes of recurrent hemoptysis and recurrent severe hemoptysis, a Cox regression model was used to identify risk factors for recurrence. Results: A total of 588 individuals were included. The median follow-up period was 34.0 months (interquartile range: 24.3–53.3 months). The 1-month, 1-year, 2-year, and 5-year cumulative recurrent hemoptysis-free rates were 87.2%, 67.5%, 57.6%, and 49.4%, respectively. The following factors were relative to recurrent hemoptysis: 24-h sputum volume (hazard ratio [HR] = 1.99 [95% confidence interval [95% CI]: 1.25–3.15, p = 0.015]), isolation of Pseudomonas aeruginosa (HR = 1.50 [95% CI: 1.13–2.00, p = 0.003]), extensive bronchiectasis (HR = 2.00 [95% CI: 1.29–3.09, p = 0.002]), and aberrant bronchial arteries (AbBAs) (HR = 1.45 [95% CI: 1.09–1.93, p = 0.014]). The area under the receiver operating characteristic curve of the nomogram was 0.728 [95% CI: 0.688–0.769]. Conclusions: Isolation of Pseudomonas aeruginosa is an important independent predictor of recurrent hemoptysis. The clearance of Pseudomonas aeruginosa might effectively reduce the hemoptysis recurrence rate.
- Open Access
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1088274
Clinical outcomes of vinorelbine loading CalliSpheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis
Background: Drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) has been used in the treatment of locally advanced lung cancer and has the potential to improve outcomes and reduce recurrence. However, DEB-BACE shows a poor therapeutic effect in advanced lung cancer after failure of multiple therapies. This study assessed the effect of DEB-BACE in the treatment of progressive lung cancer with refractory obstructive atelectasis.Methods: Progressive advanced lung cancer patients with refractory obstructive atelectasis were voluntarily enrolled in this study after failure of multiple conventional therapies. Baseline information, DEB-BACE treatment process, and changes in clinical symptoms were recorded. The primary endpoints were the objective response rate (ORR) and improvement rate of dyspnea. The secondary endpoints were time-to-progression (TTP), overall survival (OS), and rate of pulmonary re-expansion. Treatment-related adverse events and serious adverse events were analyzed to assess the safety of DEB-BACE. The Cox regression model was performed to analyze the possible factors impacting prognosis of DEB-BACE.Results: DEB-BACE was successfully performed with CalliSpheres beads loaded with vinorelbine in the 20 enrolled patients. ORR and disease control rate were 80% and 85%, respectively, at the first follow-up (43.4 ± 15.26 days). The improvement rate of dyspnea was 85% and 80% at 1 week and 1 month (p < 0.0001, p < 0.0001), respectively. TTP was 41.25 ± 14.43 days and 89.55 ± 61.7 days before and after DEB-BACE, respectively; DEB-BACE delayed the progression of advanced lung cancer (p < 0.0001). OS was 238.03 ± 33.74 days (95% confidence interval: 171.9–304.16). The rate of pulmonary re-expansion was 80% at the first follow-up. The reasons for poor prognosis were tumor necrosis, longer disease duration, and pulmonary atelectasis duration (p = 0.012, p = 0.038, p = 0.029). Massive hemoptysis was observed in two cases, and one patient died of asphyxia caused by hemoptysis. Moderate hemoptysis occurred in one case. All three adverse events were considered as the result of the tumor cavity after DEB-BACE.Conclusion: DEB-BACE loaded with vinorelbine is a feasible option for progressive advanced lung cancer with obstructive atelectasis after failure of other treatments.
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1088274
Open AccessClinical outcomes of vinorelbine loading CalliSpheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis
Background: Drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) has been used in the treatment of locally advanced lung cancer and has the potential to improve outcomes and reduce recurrence. However, DEB-BACE shows a poor therapeutic effect in advanced lung cancer after failure of multiple therapies. This study assessed the effect of DEB-BACE in the treatment of progressive lung cancer with refractory obstructive atelectasis.Methods: Progressive advanced lung cancer patients with refractory obstructive atelectasis were voluntarily enrolled in this study after failure of multiple conventional therapies. Baseline information, DEB-BACE treatment process, and changes in clinical symptoms were recorded. The primary endpoints were the objective response rate (ORR) and improvement rate of dyspnea. The secondary endpoints were time-to-progression (TTP), overall survival (OS), and rate of pulmonary re-expansion. Treatment-related adverse events and serious adverse events were analyzed to assess the safety of DEB-BACE. The Cox regression model was performed to analyze the possible factors impacting prognosis of DEB-BACE.Results: DEB-BACE was successfully performed with CalliSpheres beads loaded with vinorelbine in the 20 enrolled patients. ORR and disease control rate were 80% and 85%, respectively, at the first follow-up (43.4 ± 15.26 days). The improvement rate of dyspnea was 85% and 80% at 1 week and 1 month (p < 0.0001, p < 0.0001), respectively. TTP was 41.25 ± 14.43 days and 89.55 ± 61.7 days before and after DEB-BACE, respectively; DEB-BACE delayed the progression of advanced lung cancer (p < 0.0001). OS was 238.03 ± 33.74 days (95% confidence interval: 171.9–304.16). The rate of pulmonary re-expansion was 80% at the first follow-up. The reasons for poor prognosis were tumor necrosis, longer disease duration, and pulmonary atelectasis duration (p = 0.012, p = 0.038, p = 0.029). Massive hemoptysis was observed in two cases, and one patient died of asphyxia caused by hemoptysis. Moderate hemoptysis occurred in one case. All three adverse events were considered as the result of the tumor cavity after DEB-BACE.Conclusion: DEB-BACE loaded with vinorelbine is a feasible option for progressive advanced lung cancer with obstructive atelectasis after failure of other treatments.
- Open Access
- 30 April 2022
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-9
Management of pulmonary arteriovenous malformations involves additional factors aside from the diameter of feeding arteries: a 3-year case-case retrospective analysis
Background: Pulmonary arteriovenous malformations (PAVMs) are rare but cause various manifestations. Although the diameter of feeding arteries has been linked to treatment decisions, relationships among the characteristics of PAVMs, clinical symptoms, and treatment effect remain unclear. The present study was performed to investigate how collective characteristics of PAVMs relate to clinical symptoms and to provide proper treatment recommendations for patients with PAVMs. Methods: We retrospectively analysed 838,447 patients’ radiographic data and medical records from January 2018 to December 2020. Patients were included if a PAVM was radiographically detected for the first time in our hospital. Ordered multivariable logistic regression and hierarchical multiple regression were performed to analyse the relationships between characteristics of PAVMs and various clinical symptoms. We investigated the management of PAVMs in four tertiary university hospitals. Results: Detection rate of PAVMs was 0.025% (207/838,447), and 37.6% of patients (78/207) also had hereditary haemorrhagic telangiectasia. Eight patients were diagnosed with bilateral diffuse PAVMs. Two hundred thirty-six lesions were detected in 199 patients, and the mean diameter of the feeding artery was 4.13 ± 1.92 mm. Most PAVMs were the simple type and located in the peripheral pulmonary area. In total, 34.3% of patients (71/207) were symptom-free; remaining patients showed various manifestations, and respiratory symptoms were most common (dyspnoea on exertion, 47.8%). The diameter of the feeding artery and the type and the number of PAVMs were correlated with hypoxaemia (P < 0.001, P < 0.001, and P = 0.037, respectively). The collective characteristics of PAVMs were not related to the severity of central nervous system symptoms (largest diameter of feeding artery, P = 0.8; largest diameter of sac, P = 0.42; number of PAVMs, P = 0.35; type of PAVMs, P = 0.99). Various symptoms were greatly relieved after treatment. The hospital investigation showed that management of PAVMs was not generally appreciated in clinical practice. Conclusions: Our study revealed a low detection rate of PAVMs and a low degree of association with hereditary haemorrhagic telangiectasia in the general population. Considering the connection between collective characteristics of PAVMs and various clinical symptoms, clinicians should consider the type and number of PAVMs, the largest diameter of the feeding artery, and clinical symptoms when managing patients with PAVMs.
- 30 April 2022
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-9
Open AccessManagement of pulmonary arteriovenous malformations involves additional factors aside from the diameter of feeding arteries: a 3-year case-case retrospective analysis
Background: Pulmonary arteriovenous malformations (PAVMs) are rare but cause various manifestations. Although the diameter of feeding arteries has been linked to treatment decisions, relationships among the characteristics of PAVMs, clinical symptoms, and treatment effect remain unclear. The present study was performed to investigate how collective characteristics of PAVMs relate to clinical symptoms and to provide proper treatment recommendations for patients with PAVMs. Methods: We retrospectively analysed 838,447 patients’ radiographic data and medical records from January 2018 to December 2020. Patients were included if a PAVM was radiographically detected for the first time in our hospital. Ordered multivariable logistic regression and hierarchical multiple regression were performed to analyse the relationships between characteristics of PAVMs and various clinical symptoms. We investigated the management of PAVMs in four tertiary university hospitals. Results: Detection rate of PAVMs was 0.025% (207/838,447), and 37.6% of patients (78/207) also had hereditary haemorrhagic telangiectasia. Eight patients were diagnosed with bilateral diffuse PAVMs. Two hundred thirty-six lesions were detected in 199 patients, and the mean diameter of the feeding artery was 4.13 ± 1.92 mm. Most PAVMs were the simple type and located in the peripheral pulmonary area. In total, 34.3% of patients (71/207) were symptom-free; remaining patients showed various manifestations, and respiratory symptoms were most common (dyspnoea on exertion, 47.8%). The diameter of the feeding artery and the type and the number of PAVMs were correlated with hypoxaemia (P < 0.001, P < 0.001, and P = 0.037, respectively). The collective characteristics of PAVMs were not related to the severity of central nervous system symptoms (largest diameter of feeding artery, P = 0.8; largest diameter of sac, P = 0.42; number of PAVMs, P = 0.35; type of PAVMs, P = 0.99). Various symptoms were greatly relieved after treatment. The hospital investigation showed that management of PAVMs was not generally appreciated in clinical practice. Conclusions: Our study revealed a low detection rate of PAVMs and a low degree of association with hereditary haemorrhagic telangiectasia in the general population. Considering the connection between collective characteristics of PAVMs and various clinical symptoms, clinicians should consider the type and number of PAVMs, the largest diameter of the feeding artery, and clinical symptoms when managing patients with PAVMs.